Updated:
Immatics N.V.
Founded in 2000 by a cohort of University of Tübingen immunologists including Hans-Georg Rammensee, Immatics grew out of decades of academic research into...
Immatics N.V.
Founded in 2000 by a cohort of University of Tübingen immunologists including Hans-Georg Rammensee, Immatics grew out of decades of academic research into the peptide presentation machinery of cancer cells. The founding insight — that tumors display unique peptide-HLA complexes never seen on healthy tissue — became the technical foundation for a pipeline that now spans autologous TCR-T cells, off-the-shelf TCR bispecific molecules, and an expanding target discovery engine. The firm went public via a SPAC merger with Arya Sciences Acquisition Corp in July 2020, listing on Nasdaq under the ticker IMTX. Immatics operates two therapeutic modalities: ACTengine, a personalized cell therapy where a patient's own T cells are engineered to express cancer-specific TCRs, and TCER, a bispecific format that links a TCR to a CD3 T-cell engager domain for off-the-shelf use. Lead candidates include IMA203, an ACTengine product targeting PRAME in melanoma and other solid tumors, and IMA401, a TCER bispecific against MAGEA4/8. The firm has disclosed clinical responses in heavily pre-treated patients, and in December 2023, the FDA granted Regenerative Medicine Advanced Therapy designation to IMA203 for certain sarcoma patients. Partnerships with Bristol Myers Squibb, Moderna, and Editas Medicine provide validation and non-dilutive funding for earlier-stage programs. Immatics employs over 300 professionals across its Tübingen headquarters, a clinical and manufacturing hub in Houston, and an expanded Munich research site. The Houston facility, built to support US-based clinical trials, houses cell therapy manufacturing suites and process development capabilities. In November 2023, the firm reported an updated cash runway into 2026 following cost-containment measures and a strategic refocus on lead candidates. Annual R&D expenditure runs in the high double-digit millions. The firm's XPRESIDENT target discovery platform, which directly profiles the immunopeptidome of tumor samples, has mapped over 1.5 million HLA-presented peptides across more than 30 solid tumor types, creating a proprietary database that feeds the TCR drug engine. Immatics differs structurally from many oncology biotechs in its vertical integration: it owns the target discovery, TCR engineering, manufacturing, and clinical development pieces end-to-end, rather than licensing in targets or relying on external partners for core discovery. The XPRESIDENT platform functions as a renewable competitive moat — each new tumor sample refines the target atlas, making the database more defensible over time. The dual-modality strategy also spreads risk across cell therapy and bispecific formats, with manufacturing complexity concentrated in the wholly-owned Houston facility rather than outsourced to CDMOs.
General information
Firm type
Asset Manager
Year founded
2000
AUM
Undisclosed
Location
Region
Europe
Country
Germany
City
Tübingen
Corporate office
Tübingen, Germany
Additional offices
Houston, TX, United States · Munich, Germany
Principals
Harpreet Singh
Chief Executive Officer
Sector focus
Frequently asked questions
How does Immatics identify cancer targets differently from other oncology companies?
Immatics uses its XPRESIDENT platform to directly analyze the immunopeptidome — the collection of peptides presented on the surface of tumor cells by HLA molecules. Rather than relying solely on genomic or transcriptomic data, this mass spectrometry-based approach identifies peptides that are actually presented and therefore visible to T cells. The platform has catalogued more than 1.5 million HLA-presented peptides across over 30 solid tumor types. The firm then applies machine learning to prioritize targets that are highly tumor-specific and never found on healthy tissue.
What therapeutic formats does Immatics use to target these cancer peptides?
Immatics has two clinical-stage platforms. ACTengine is an autologous cell therapy where a patient's T cells are extracted, engineered with a TCR that recognizes a specific cancer target, and reinfused. TCER is a bispecific format that fuses a tumor-specific TCR to an anti-CD3 T-cell engager, creating an off-the-shelf molecule that redirects a patient's existing T cells to attack the tumor. The firm's lead ACTengine candidate, IMA203, targets PRAME, and its lead TCER candidate, IMA401, targets MAGEA4/8.
Did Immatics go public, and if so, through what mechanism?
Immatics went public on the Nasdaq in July 2020 through a SPAC merger with Arya Sciences Acquisition Corp, a blank-check company formed by Perceptive Advisors. The transaction valued Immatics at roughly $2 billion at the time of listing. The ticker symbol is IMTX.
What clinical-stage partnerships does Immatics have?
Immatics has active partnerships with Bristol Myers Squibb, Moderna, and Editas Medicine. The BMS collaboration, signed in 2019 and expanded in 2021, focuses on TCR bispecific molecules. The Moderna partnership, announced in 2023, combines Immatics' TCR discovery with Moderna's mRNA platform to create mRNA-encoded TCR therapeutics. The Editas collaboration, signed in 2020, combines CRISPR gene editing with TCR engineering.
Who runs investment decisions at Immatics?
Immatics is a publicly traded biotech, not an investment firm. Capital allocation and strategic decisions are made by the management board led by CEO Harpreet Singh, with oversight from a supervisory board chaired by Peter Chambré. Major strategic moves — such as partnerships with BMS and Moderna, the 2020 SPAC listing, and the 2023 pipeline prioritization — are disclosed in regulatory filings and press releases.
Why does Immatics maintain a significant operational presence in Houston, Texas?
The Houston facility was established to support US-based clinical trials, which represent a substantial portion of Immatics' development activity. It houses cell therapy manufacturing suites, process development, and quality control laboratories. Running US trials with a domestic manufacturing footprint reduces logistical complexity for autologous cell therapies, where patient cells must be collected, engineered, and reinfused within a tight timeframe.
What is Immatics' known posture on fundraising and capital markets?
As a publicly traded company, Immatics accesses capital through equity markets and partnership revenue rather than traditional fund structures. The 2020 SPAC listing provided initial post-merger funding, and subsequent capital has come from follow-on offerings and upfront payments from pharmaceutical partners. The firm disclosed a cash runway into 2026 as of its November 2023 update, following a restructuring that focused resources on lead clinical programs.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: